SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Müllers Erik) srt2:(2024)"

Search: WFRF:(Müllers Erik) > (2024)

  • Result 1-3 of 3
Sort/group result
   
EnumerationReferenceCoverFind
1.
  • Fredin Haslum, Johan, et al. (author)
  • Cell Painting-based bioactivity prediction boosts high-throughput screening hit-rates and compound diversity
  • 2024
  • In: Nature Communications. - : Springer Nature. - 2041-1723. ; 15:1
  • Journal article (peer-reviewed)abstract
    • Identifying active compounds for a target is a time- and resource-intensive task in early drug discovery. Accurate bioactivity prediction using morphological profiles could streamline the process, enabling smaller, more focused compound screens. We investigate the potential of deep learning on unrefined single-concentration activity readouts and Cell Painting data, to predict compound activity across 140 diverse assays. We observe an average ROC-AUC of 0.744 ± 0.108 with 62% of assays achieving ≥0.7, 30% ≥0.8, and 7% ≥0.9. In many cases, the high prediction performance can be achieved using only brightfield images instead of multichannel fluorescence images. A comprehensive analysis shows that Cell Painting-based bioactivity prediction is robust across assay types, technologies, and target classes, with cell-based assays and kinase targets being particularly well-suited for prediction. Experimental validation confirms the enrichment of active compounds. Our findings indicate that models trained on Cell Painting data, combined with a small set of single-concentration data points, can reliably predict the activity of a compound library across diverse targets and assays while maintaining high hit rates and scaffold diversity. This approach has the potential to reduce the size of screening campaigns, saving time and resources, and enabling primary screening with more complex assays.
  •  
2.
  • Fredin Haslum, Johan (author)
  • Machine Learning Methods for Image-based Phenotypic Profiling in Early Drug Discovery
  • 2024
  • Doctoral thesis (other academic/artistic)abstract
    • In the search for new therapeutic treatments, strategies to make the drug discovery process more efficient are crucial. Image-based phenotypic profiling, with its millions of pictures of fluorescent stained cells, is a rich and effective means to capture the morphological effects of potential treatments on living systems. Within this complex data await biological insights and new therapeutic opportunities – but computational tools are needed to unlock them.This thesis examines the role of machine learning in improving the utility and analysis of phenotypic screening data. It focuses on challenges specific to this domain, such as the lack of reliable labels that are essential for supervised learning, as well as confounding factors present in the data that are often unavoidable due to experimental variability. We explore transfer learning to boost model generalization and robustness, analyzing the impact of domain distance, initialization, dataset size, and architecture on the effectiveness of applying natural domain pre-trained weights to biomedical contexts. Building upon this, we delve into self-supervised pretraining for phenotypic image data, but find its direct application is inadequate in this context as it fails to differentiate between various biological effects. To overcome this, we develop new self-supervised learning strategies designed to enable the network to disregard confounding experimental noise, thus enhancing its ability to discern the impacts of various treatments. We further develop a technique that allows a model trained for phenotypic profiling to be adapted to new, unseen data without the need for any labels or supervised learning. Using this approach, a general phenotypic profiling model can be readily adapted to data from different sites without the need for any labels. Beyond our technical contributions, we also show that bioactive compounds identified using the approaches outlined in this thesis have been subsequently confirmed in biological assays through replication in an industrial setting. Our findings indicate that while phenotypic data and biomedical imaging present complex challenges, machine learning techniques can play a pivotal role in making early drug discovery more efficient and effective.
  •  
3.
  • Rigal, Sophie, et al. (author)
  • Normoglycemia and physiological cortisone level maintain glucose homeostasis in a pancreas-liver microphysiological system
  • 2024
  • In: Communications Biology. - : NATURE PORTFOLIO. - 2399-3642. ; 7:1
  • Journal article (peer-reviewed)abstract
    • Current research on metabolic disorders and diabetes relies on animal models because multi-organ diseases cannot be well studied with standard in vitro assays. Here, we have connected cell models of key metabolic organs, the pancreas and liver, on a microfluidic chip to enable diabetes research in a human-based in vitro system. Aided by mechanistic mathematical modeling, we demonstrate that hyperglycemia and high cortisone concentration induce glucose dysregulation in the pancreas-liver microphysiological system (MPS), mimicking a diabetic phenotype seen in patients with glucocorticoid-induced diabetes. In this diseased condition, the pancreas-liver MPS displays beta-cell dysfunction, steatosis, elevated ketone-body secretion, increased glycogen storage, and upregulated gluconeogenic gene expression. Conversely, a physiological culture condition maintains glucose tolerance and beta-cell function. This method was reproducible in two laboratories and was effective in multiple pancreatic islet donors. The model also provides a platform to identify new therapeutic proteins, as demonstrated with a combined transcriptome and proteome analysis. A human-cell-based pancreas-liver microphysiological system serves as a preclinical platform for studying glucose-insulin homeostasis and disease mechanisms of glucose dysregulation, offering a tool for identifying targets and testing drugs.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-3 of 3

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view